<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04475926</url>
  </required_header>
  <id_info>
    <org_study_id>SRP-LGMD-501-NHS</org_study_id>
    <nct_id>NCT04475926</nct_id>
  </id_info>
  <brief_title>A Study of the Natural History of Patients With LGMD2E/R4, LGMD2D/R3, and LGMD2C/R5, ≥ 4 Years of Age, Who Are Managed in Routine Clinical Practice</brief_title>
  <official_title>Journey: A Global, Multicenter, Longitudinal Study of the Natural History of Subjects With Limb Girdle Muscular Dystrophy (LGMD) Type 2E (LGMD2E/R4), Type 2D (LGMD2D/R3), and Type 2C (LGMD2C/R5)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sarepta Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sarepta Therapeutics, Inc.</source>
  <brief_summary>
    <textblock>
      This study will follow patients who are screened and confirmed with a genetic diagnosis of&#xD;
      Limb-girdle muscular dystrophy type 2E (LGMD2E/R4), Limb-girdle muscular dystrophy type 2D&#xD;
      (LGMD2D/R3), or Limb-girdle muscular dystrophy type 2C (LGMD2C/R5). These enrolled patients&#xD;
      will be followed to evaluate mobility and pulmonary function for up to 3 years after&#xD;
      enrollment. Additional patient data will be collected from the time the individual began&#xD;
      experiencing LGMD symptoms to the present.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 22, 2021</start_date>
  <completion_date type="Anticipated">December 24, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 24, 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>North Star Assessment for Dysferlinopathy (NSAD) Total Score</measure>
    <time_frame>Baseline up to Month 36</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Rise from the Floor</measure>
    <time_frame>Baseline up to Month 36</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time of 10-Meter Walk/Run [10MWR]</measure>
    <time_frame>Baseline up to Month 36</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Ascend 4 Steps</measure>
    <time_frame>Baseline up to Month 36</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Dimension of the Performance of the Upper Limb (PUL)</measure>
    <time_frame>Baseline up to Month 36</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Timed Up and Go (TUG)</measure>
    <time_frame>Baseline up to Month 36</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time of 100-Meter Walk/Run (100MWR)</measure>
    <time_frame>Baseline up to Month 36</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pulmonary Function Test: Forced Vital Capacity (FVC)</measure>
    <time_frame>Baseline up to Month 36</time_frame>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Limb-girdle Muscular Dystrophy</condition>
  <arm_group>
    <arm_group_label>LGMD2E/R4 Cohort</arm_group_label>
    <description>Patients with LGMD2E/R4 will be enrolled in this cohort. Enrollment will be capped according to age as follows: 4 to &lt;8 years age range, 8 to &lt;14 years age range, and ≥14 years age range through the course of the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LGMD2D/R3 Cohort</arm_group_label>
    <description>Patients with LGMD2D/R3 will be enrolled in this cohort. Enrollment will be capped according to age as follows: 4 to &lt;8 years age range, 8 to &lt;14 years age range, and ≥14 years age range through the course of the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LGMD2C/R5 Cohort</arm_group_label>
    <description>Patients with LGMD2C/R5 will be enrolled in this cohort. Enrollment will be capped according to age as follows: 4 to &lt;8 years age range, 8 to &lt;14 years age range, and ≥14 years age range through the course of the study.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        The population for this study is ambulatory or non-ambulatory patients ≥ 4 years of age&#xD;
        with confirmed genetic diagnosis of LGMD2E/R4, LGMD2D/R3, or LGMD2C/R5.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female patient ≥ 4 years of age with confirmed genetic diagnosis of LGMD2E/R4,&#xD;
             LGMD2D/R3, or LGMD2C/R5.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Demonstrates cognitive delay or impairment that could confound motor development, in&#xD;
             the opinion of the Investigator.&#xD;
&#xD;
          -  Has a medical condition, in the opinion of the Investigator, that might compromise&#xD;
             patients ability to comply with study requirements.&#xD;
&#xD;
          -  Is participating in other interventional study(ies) at the time of enrollment in this&#xD;
             study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Sarepta Therapeutics, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Medical Information</last_name>
    <phone>+1-800-690-2003</phone>
    <email>clinicaltrials@sarepta.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Barrow Neurological Institute</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85013</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Strong</last_name>
      <phone>602-406-4771</phone>
      <email>Fulton.research@dignityhealth.org</email>
    </contact>
    <investigator>
      <last_name>Bill Jacobsen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Arkansas Children's</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Annette Guy</last_name>
      <email>guyea@archildrens.org</email>
    </contact>
    <investigator>
      <last_name>Aravindhan Veerapandiyan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Anne &amp; Robert H. Lurie Children's Hospital of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathleen Meeks</last_name>
      <phone>312-227-0067</phone>
      <email>katmeeks@luriechildrens.org</email>
    </contact>
    <investigator>
      <last_name>Vamshi Rao, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nationwide Children's Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kiana Shannon</last_name>
      <phone>614-722-6881</phone>
      <email>kiana.shannon@nationwidechildrens.org</email>
    </contact>
    <investigator>
      <last_name>Linda Lowes, PT, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of the King's Daughters</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cara Headrick</last_name>
      <phone>757-688-6417</phone>
      <email>cara.headrick@chkd.org</email>
    </contact>
    <investigator>
      <last_name>Crystal Proud, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>July 14, 2020</study_first_submitted>
  <study_first_submitted_qc>July 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 17, 2020</study_first_posted>
  <last_update_submitted>June 18, 2021</last_update_submitted>
  <last_update_submitted_qc>June 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>North Star Assessment for Dysferlinopathy (NSAD)</keyword>
  <keyword>Performance of Upper Limb (PUL)</keyword>
  <keyword>Pulmonary function tests (PFTs)</keyword>
  <keyword>Ambulatory</keyword>
  <keyword>Non-Ambulatory</keyword>
  <keyword>Limb-girdle</keyword>
  <keyword>LGMD</keyword>
  <keyword>sarcoglycanopathy</keyword>
  <keyword>β -sarcoglycan</keyword>
  <keyword>Muscular Dystrophy</keyword>
  <keyword>α - sarcoglycan</keyword>
  <keyword>γ - sarcoglycan</keyword>
  <keyword>LGMD-2D/R3</keyword>
  <keyword>LGMD-2E/R4</keyword>
  <keyword>LGMD-2C/R5</keyword>
  <keyword>Clinical Outcomes Assessment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscular Dystrophies</mesh_term>
    <mesh_term>Muscular Dystrophies, Limb-Girdle</mesh_term>
    <mesh_term>Sarcoglycanopathies</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

